Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity

The company presented data for the menin inhibitor in KMT2Ar acute leukemias in an ASH late-breaker. The larger addressable population, including mNPM1 AML, could be a $2bn opportunity.